Head-to-head evidence
deucravacitinib vs HS-10374
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
deucravacitinib · Sotyktu
Marketed by Bristol-Myers Squibb
NCT03611751 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled trial of 1,020 participants. Both primary clinical endpoints at week 16 were met: deucravacitinib produced significantly more participants with sPGA 0/1 and PASI 75 responses than placebo.
Next expected readout: November 2026 · NCT05570955 (registry estimate)
HS-10374
Developed by Hansoh Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: deucravacitinib's landscape · HS-10374's landscape